Skip to main content
Premium Trial:

Request an Annual Quote

Byron Hewett, Edward Erickson, John Anson, William Slikker Jr.


Immunicon said recently that it has elected Byron Hewett as president and CEO, and a company director. Hewett is currently president and COO of the company.

In addition, Immunicon said that Edward Erickson, the company's chairman and CEO, will serve as executive chairman through March 31, and thereafter remain as chairman of the board in a non-executive capacity.

Hewett has served as Immunicon's president and COO since April 2005. Prior to that, he was also the company's general manager of cancer products. He joined Immunicon from Qiagen, where he served as senior vice president of sales and marketing and general manager for North America. He has also served as vice president of worldwide marketing in the laboratory testing segment of Bayer Diagnostics, president of US commercial operations for Bayer, and business unit manager for Abbott Laboratories. He holds a BS from the McIntire School of Commerce at the University of Virginia, and an MBA from the Kellogg Graduate School of Management at Northwestern University.

Oxford Gene Technology appointed John Anson as research and development director, the company said recently.

Anson spent 16 years at Amersham Biosciences/GE Healthcare where he held various executive positions, including head of product development. He worked on his post-doctorate research at PHLS Centre for Applied Microbiology and Research, Porton Down, and holds a PhD in bacterial genetics from Cranfield University and a BSc in microbiology from the University of Kent.

William Slikker Jr. has been named as the acting director of the National Center for Toxicological Research, the US Food and Drug Administration announced recently.

Slikker replaces Dan Casciano, the NCTR director for more than six years. Casciano is moving into the private sector to work on molecular, cellular, and general toxicology issues.

Most recently, Slikker was NCTR's deputy center director for research. He received his BA in biology from the University of California, Santa Barbara and a PhD in pharmacology and toxicology from the University of California, Davis.